Summary of project PR002572
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002572. The data can be accessed directly via it's Project DOI: 10.21228/M86540 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Project ID: | PR002572 |
| Project DOI: | doi: 10.21228/M86540 |
| Project Title: | Lipidomics analysis of PNPLA3 wild type and PNPLA3 I148M mutant Hep3B cells. |
| Project Type: | Lipidomics |
| Project Summary: | The PNPLA3(I148M) mutation is associated with increased risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD). To better understand how PNPLA3(I148M) mutation impacts hepatic lipid metabolism, we conducted lipidomics analysis from Hep3B cells expressing wild type or I148M mutant PNPLA3 and cultured in media plus or minus oleic acid. Our studies revealed widespread changes in the lipidomic profiles of Hep3B cells expressing PNPLA3(I148M) compared to Hep3B cells expressing wild type PNPLA3, particularly after exposure to exogenous oleic acid in the culture media. Of particular note, we report decreases in the relative abundance of phosphatidylcholines and other phospholipids containing polyunsaturated fatty acids (PUFA) like arachidonic acid. These changes in phospholipid PUFA content lead to changes in membrane fluidity that impact the ability of cells carrying the PNPLA3(I148M) to secrete apolipoprotein B (apoB)-rich very low density lipoproteins. This impaired lipid secretory phenotype leads to an accumulation of triglycerides, which was verified by our lipidomics observation that Hep3B cells expressing PNPLA3(I148M) contain increases in the relative abundance of many triglycerides relative to PNPLA3 wild type Hep3B cells. |
| Institute: | Amgen |
| Last Name: | LaGory |
| First Name: | Edward |
| Address: | 750 Gateway Blvd, South San Francisco, CA 94080 |
| Email: | elagory@amgen.com |
| Phone: | +1 (650) 244-2333 |
Summary of all studies in project PR002572
| Study ID | Study Title | Species | Institute | Analysis(* : Contains Untargted data) | Release Date | Version | Samples | Download(* : Contains raw data) |
|---|---|---|---|---|---|---|---|---|
| ST004095 | Hep3B PNPLA3 wild type and PNPLA3(I148M) lipidomics | Homo sapiens | Amgen | MS | 2025-08-12 | 1 | 48 | Uploaded data (7.5G)* |
| ST004110 | Lipidomics characterization from plasma VLDL fractions isolated from human PNPLA3 wild type and human PNPLA3(I148M) knock in mice. | Mus musculus | Amgen | MS | 2025-08-14 | 1 | 52 | Uploaded data (8.3G)* |
| ST004118 | Lipidomics on Hep3B Cells Overexpressing CGI-158 and PNPLA2 | Homo sapiens | Amgen | MS | 2025-09-09 | 1 | 18 | Uploaded data (3.6G)* |
